Lysyl-tRNA synthetase (KRS) expression in gastric carcinoma and tumor-associated inflammation

Baek-Hui Kim, Woon Yong Jung, Hyunjoo Lee, Youngran Kang, You-Jin Jang, Soon Won Hong, Hyeong Jae Jeong, Sun Och Yoon

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background: Lysyl-tRNA synthetase (KRS) is an aminoacyl-tRNA synthetase (ARS) that is essential for protein synthesis during ligation of specific amino acids to their cognate tRNAs. Aberrant expression of ARSs is associated with various human cancers. Methods: Using immunohistochemical detection, the present study analyzed the clinical relevance of KRS expression in tumor cells and tumor-associated inflammatory cells (TAI) in 457 patients who underwent curative radical surgery and standard adjuvant therapy and who were observed on long-term follow-up. Results: High expression of KRS in tumor cells (tumor-KRS(+)) was noted in 43.3 % (198 of 457) of cases. High expression of KRS in tumor-associated inflammatory cells (TAI-KRS(+)) including macrophages/monocytes, CD4-positive T cells, and/or neutrophils was observed in 37.2 % (170 of 457) of cases. Status of KRS in the tumor and TAI revealed an association with the known clinicopathological parameters for prognosis of gastric cancer. Tumor-KRS(+) status correlated to shorter overall survival, especially in stage III to IV cancers (P = 0.003), while TAI-KRS(+) status correlated significantly to longer overall survival in gastric cancer (P = 0.049). Cases with tumor-KRS(+) and TAI-KRS(-) status showed significantly reduced survival rates compared to those of other cases (P = 0.010), and status of tumor-KRS(+) and TAI-KRS(-) was revealed as an independently poor prognostic factor of overall survival (P = 0.001). Conclusions: KRS-related inflammation can be identified in a subset of gastric cancer. This may be a possible mechanism of immune surveillance against tumor progression. In addition, expression status of KRS in tumor and TAI may be an independent prognostic marker for gastric cancer patients.

Original languageEnglish
Pages (from-to)2020-2027
Number of pages8
JournalAnnals of Surgical Oncology
Volume21
Issue number6
DOIs
Publication statusPublished - 2014 Jan 1

Fingerprint

Lysine-tRNA Ligase
Stomach
Inflammation
Carcinoma
Neoplasms
Stomach Neoplasms
Survival

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Lysyl-tRNA synthetase (KRS) expression in gastric carcinoma and tumor-associated inflammation. / Kim, Baek-Hui; Jung, Woon Yong; Lee, Hyunjoo; Kang, Youngran; Jang, You-Jin; Hong, Soon Won; Jeong, Hyeong Jae; Yoon, Sun Och.

In: Annals of Surgical Oncology, Vol. 21, No. 6, 01.01.2014, p. 2020-2027.

Research output: Contribution to journalArticle

Kim, Baek-Hui ; Jung, Woon Yong ; Lee, Hyunjoo ; Kang, Youngran ; Jang, You-Jin ; Hong, Soon Won ; Jeong, Hyeong Jae ; Yoon, Sun Och. / Lysyl-tRNA synthetase (KRS) expression in gastric carcinoma and tumor-associated inflammation. In: Annals of Surgical Oncology. 2014 ; Vol. 21, No. 6. pp. 2020-2027.
@article{587c432213054adc873fe6eb182350e4,
title = "Lysyl-tRNA synthetase (KRS) expression in gastric carcinoma and tumor-associated inflammation",
abstract = "Background: Lysyl-tRNA synthetase (KRS) is an aminoacyl-tRNA synthetase (ARS) that is essential for protein synthesis during ligation of specific amino acids to their cognate tRNAs. Aberrant expression of ARSs is associated with various human cancers. Methods: Using immunohistochemical detection, the present study analyzed the clinical relevance of KRS expression in tumor cells and tumor-associated inflammatory cells (TAI) in 457 patients who underwent curative radical surgery and standard adjuvant therapy and who were observed on long-term follow-up. Results: High expression of KRS in tumor cells (tumor-KRS(+)) was noted in 43.3 {\%} (198 of 457) of cases. High expression of KRS in tumor-associated inflammatory cells (TAI-KRS(+)) including macrophages/monocytes, CD4-positive T cells, and/or neutrophils was observed in 37.2 {\%} (170 of 457) of cases. Status of KRS in the tumor and TAI revealed an association with the known clinicopathological parameters for prognosis of gastric cancer. Tumor-KRS(+) status correlated to shorter overall survival, especially in stage III to IV cancers (P = 0.003), while TAI-KRS(+) status correlated significantly to longer overall survival in gastric cancer (P = 0.049). Cases with tumor-KRS(+) and TAI-KRS(-) status showed significantly reduced survival rates compared to those of other cases (P = 0.010), and status of tumor-KRS(+) and TAI-KRS(-) was revealed as an independently poor prognostic factor of overall survival (P = 0.001). Conclusions: KRS-related inflammation can be identified in a subset of gastric cancer. This may be a possible mechanism of immune surveillance against tumor progression. In addition, expression status of KRS in tumor and TAI may be an independent prognostic marker for gastric cancer patients.",
author = "Baek-Hui Kim and Jung, {Woon Yong} and Hyunjoo Lee and Youngran Kang and You-Jin Jang and Hong, {Soon Won} and Jeong, {Hyeong Jae} and Yoon, {Sun Och}",
year = "2014",
month = "1",
day = "1",
doi = "10.1245/s10434-014-3522-z",
language = "English",
volume = "21",
pages = "2020--2027",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "6",

}

TY - JOUR

T1 - Lysyl-tRNA synthetase (KRS) expression in gastric carcinoma and tumor-associated inflammation

AU - Kim, Baek-Hui

AU - Jung, Woon Yong

AU - Lee, Hyunjoo

AU - Kang, Youngran

AU - Jang, You-Jin

AU - Hong, Soon Won

AU - Jeong, Hyeong Jae

AU - Yoon, Sun Och

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Background: Lysyl-tRNA synthetase (KRS) is an aminoacyl-tRNA synthetase (ARS) that is essential for protein synthesis during ligation of specific amino acids to their cognate tRNAs. Aberrant expression of ARSs is associated with various human cancers. Methods: Using immunohistochemical detection, the present study analyzed the clinical relevance of KRS expression in tumor cells and tumor-associated inflammatory cells (TAI) in 457 patients who underwent curative radical surgery and standard adjuvant therapy and who were observed on long-term follow-up. Results: High expression of KRS in tumor cells (tumor-KRS(+)) was noted in 43.3 % (198 of 457) of cases. High expression of KRS in tumor-associated inflammatory cells (TAI-KRS(+)) including macrophages/monocytes, CD4-positive T cells, and/or neutrophils was observed in 37.2 % (170 of 457) of cases. Status of KRS in the tumor and TAI revealed an association with the known clinicopathological parameters for prognosis of gastric cancer. Tumor-KRS(+) status correlated to shorter overall survival, especially in stage III to IV cancers (P = 0.003), while TAI-KRS(+) status correlated significantly to longer overall survival in gastric cancer (P = 0.049). Cases with tumor-KRS(+) and TAI-KRS(-) status showed significantly reduced survival rates compared to those of other cases (P = 0.010), and status of tumor-KRS(+) and TAI-KRS(-) was revealed as an independently poor prognostic factor of overall survival (P = 0.001). Conclusions: KRS-related inflammation can be identified in a subset of gastric cancer. This may be a possible mechanism of immune surveillance against tumor progression. In addition, expression status of KRS in tumor and TAI may be an independent prognostic marker for gastric cancer patients.

AB - Background: Lysyl-tRNA synthetase (KRS) is an aminoacyl-tRNA synthetase (ARS) that is essential for protein synthesis during ligation of specific amino acids to their cognate tRNAs. Aberrant expression of ARSs is associated with various human cancers. Methods: Using immunohistochemical detection, the present study analyzed the clinical relevance of KRS expression in tumor cells and tumor-associated inflammatory cells (TAI) in 457 patients who underwent curative radical surgery and standard adjuvant therapy and who were observed on long-term follow-up. Results: High expression of KRS in tumor cells (tumor-KRS(+)) was noted in 43.3 % (198 of 457) of cases. High expression of KRS in tumor-associated inflammatory cells (TAI-KRS(+)) including macrophages/monocytes, CD4-positive T cells, and/or neutrophils was observed in 37.2 % (170 of 457) of cases. Status of KRS in the tumor and TAI revealed an association with the known clinicopathological parameters for prognosis of gastric cancer. Tumor-KRS(+) status correlated to shorter overall survival, especially in stage III to IV cancers (P = 0.003), while TAI-KRS(+) status correlated significantly to longer overall survival in gastric cancer (P = 0.049). Cases with tumor-KRS(+) and TAI-KRS(-) status showed significantly reduced survival rates compared to those of other cases (P = 0.010), and status of tumor-KRS(+) and TAI-KRS(-) was revealed as an independently poor prognostic factor of overall survival (P = 0.001). Conclusions: KRS-related inflammation can be identified in a subset of gastric cancer. This may be a possible mechanism of immune surveillance against tumor progression. In addition, expression status of KRS in tumor and TAI may be an independent prognostic marker for gastric cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=84902172449&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902172449&partnerID=8YFLogxK

U2 - 10.1245/s10434-014-3522-z

DO - 10.1245/s10434-014-3522-z

M3 - Article

VL - 21

SP - 2020

EP - 2027

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 6

ER -